Actively Recruiting
A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma
Led by Aalborg University Hospital · Updated on 2025-11-25
354
Participants Needed
4
Research Sites
113 weeks
Total Duration
On this page
Sponsors
A
Aalborg University Hospital
Lead Sponsor
O
Odense University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Chronic subdural hematoma (CSDH) is a common disease. The main treatment is neurosurgical evacuation and subsequent hematoma drainage. However, consensus on the optimal drain placement site, and whether the drainage should be active or passive, is lacking. The aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH. The study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark. Adult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides. Before surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage. The patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence. Secondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures. Sample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years. Ethics approval for inclusion of competent patients has been obtained (N-20240009).
CONDITIONS
Official Title
A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (≥ 18 years)
- Symptomatic chronic subdural hematoma confirmed by brain CT or MRI
- Admitted to a Danish neurosurgical department for surgical treatment
- Undergoing a single burr-hole evacuation
- Able to give informed written and oral consent prior to surgery
You will not qualify if you...
- Mentally incapacitated patients
- Known abnormalities in cerebrospinal fluid (protein, glucose levels, cell count, and type)
- Abnormal cerebrospinal fluid dynamics (e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, ventricular peritoneal shunt)
- Additional or previous intracranial pathology requiring neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess)
- Recurrent chronic subdural hematoma or previous craniotomy or other transcranial surgery
- Unable to give informed consent prior to surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Department of Neurosurgery, Aalborg University Hospital
Aalborg, Denmark, 9000
Actively Recruiting
2
Department of Neurosurgery, Aarhus University Hospital
Aarhus, Denmark, 8000
Actively Recruiting
3
Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
4
Department of Neurosurgery, Odense University Hospital
Odense, Denmark, 5100
Actively Recruiting
Research Team
C
Carsten R Bjarkam, Professor, Ph.D., DMSc.
CONTACT
R
Rares Miscov, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here